Search for: [Abstract = "0.81, P=0.15\) to the clinical model did not improve its discriminatory ability. Our results suggest that due to the limited predictive value, LBP and sCD14 could not be recommended as biomarkers of SAP for the clinical practice. The aim of the third study was to determine if there is any association between anticholinergic medication used before stroke and SAP. Prospectively collected data of 675 patients with acute stroke \(mean age\: 71.4±13.3\; 53.1% women\) were analyzed. The Anticholinergic Drug Scale \(ADS\) was used to assess anticholinergic exposure during a month preceding stroke onset. ADS is a well\-established scale which correlates with serum anticholinergic activity. SAP was diagnosed in 14.7% of patients. The use of anticholinergic medication before stroke was associated with an elevated risk of SAP \(OR\: 2.56, 95% CI\: 1.59\-4.11, P<0.01\) in univariate analysis. This association remained significant in multivariable analysis adjusted for age, stroke severity, atrial fibrillation, previous myocardial infarction and respiratory tract diseases \(OR\: 2.06, 95% CI\: 1.01\-4.22, P=0.04\). The results of the study suggest that the use of anticholinergic medication before stroke is associated with an increased risk of SAP."]

Number of results: 1